Home Newsfeeds Theratechnologies Highlights Trogarzo Data At AIDS 2022; Co Says Data Shows Potential for Improved Treatment Regimens

Theratechnologies Highlights Trogarzo Data At AIDS 2022; Co Says Data Shows Potential for Improved Treatment Regimens

New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents. Predictive pharmacokinetic modelling shows that new methods of

byBenzinga Newsdesk

July 28, 2022

1 minute read

New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents.
Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion.
- Additional data highlights synergistic activities between Trogarzo and dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational antiretroviral therapy (ARV).

Citigroup Maintains Neutral on Under Armour, Raises Price Target to $13

By Benzinga Newsdesk

February 1, 10:42 AM

Citigroup analyst Paul Lejuez maintains Under Armour (NYSE:UAA) with a Neutral and raises the price target from $8 to $13.

News

Generative AI On The Rise: 93% Of Companies To Boost Spending, US May Fall Behind

By Chris Katje

August 10, 9:00 AM

Over the last two years, companies have been faced with questions on spending and business opportunities related to increasing use cases of artificial intelligence. A new study reveals how much growth companies could put into generative artificial intelligence spending.

MSFT

RBC Capital Initiates Coverage On General Dynamics with Outperform Rating, Announces Price Target of $275

By Benzinga Newsdesk

August 30, 4:59 AM

RBC Capital analyst Michael Eisen initiates coverage on General Dynamics (NYSE:GD) with a Outperform rating and announces Price Target of $275.

Japanese Stocks Rallied Five Weeks In A Row After Warren Buffett’s Bet, Outperforming A Nearly Flat S&P 500

By Piero Cingari

May 15, 7:30 PM

Since Warren Buffett expressed willingness to raise his exposures to Japanese trading companies on April 10, the Nikkei 225 index, which represents the broad Japanese stock market, registered gains for five straight weeks, increasing by 8% and surging

DXJ

Theratechnologies Highlights Trogarzo Data At AIDS 2022; Co Says Data Shows Potential for Improved Treatment Regimens

Related Posts

Citigroup Maintains Neutral on Under Armour, Raises Price Target to $13

Generative AI On The Rise: 93% Of Companies To Boost Spending, US May Fall Behind

RBC Capital Initiates Coverage On General Dynamics with Outperform Rating, Announces Price Target of $275

Japanese Stocks Rallied Five Weeks In A Row After Warren Buffett’s Bet, Outperforming A Nearly Flat S&P 500